Dr. Scott, of Berkley, Calif., was in an intensive care unit with an acute illness for 10 days before his death, NPR reported Dec. 18.
He began studying the drug previously known as Oculinum, in the 1970s and 1980s with the goal of helping patients with eye disorders avoid extensive surgeries. In 1991, Dr. Scott sold the drug to Allergan, which officially changed the drug’s name to Botox the next year. The drug’s use was then expanded to include other ailments, such as migraines, and for cosmetic use to remove wrinkles.
“I think that’s a charming, slightly frivolous use,” Dr. Scott told SF Gate in 2002, regarding the drug’s use for cosmetic purposes. “It’s not along the lines of what I was into — applications for serious disorders.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.